Tags

Type your tag names separated by a space and hit enter

Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
Dermatology. 2004; 209(1):46-9.D

Abstract

BACKGROUND

Cutaneous leishmaniasis is an endemic disease in developing countries. The first-line drugs for its treatment are the pentavalent antimony compounds such as meglumine antimoniate (MA). High cost, side effects, multiple injections and incomplete efficacy are limitations of this therapy. Zinc sulfate (ZS) has been reported to be effective in the treatment of cutaneous leishmaniasis.

OBJECTIVE

To compare the efficacy of intralesional injections of ZS 2% with those of MA in the treatment of cutaneous leishmaniasis.

METHODS

This was a prospective, double-blind, case-control clinical study. 104 patients with typical lesions of acute cutaneous leishmaniasis (ACL) were included. The duration of treatment was 6 weeks. Improvement was evaluated by clinical examination and direct smear.

RESULTS

The study was completed in only 66 patients: 35 patients received MA and 31 received ZS. The cure rates were 60% for MA and 83.8% for ZS. After the second and fourth weeks, the efficacy of treatment with ZS was higher than that with MA (p < 0.01), but after 6 weeks no significant differences were observed between the two groups (p > 0.05).

CONCLUSION

On the basis of this trial and despite the high number of drop-outs, we consider that the intralesional injection of ZS 2% is an alternative treatment in ACL.

Authors+Show Affiliations

Isfahan University of Medical Science and Health Services, Isfahan, Iran. Iraji@med.mui.ac.irNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15237267

Citation

Iraji, Fariba, et al. "Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis." Dermatology (Basel, Switzerland), vol. 209, no. 1, 2004, pp. 46-9.
Iraji F, Vali A, Asilian A, et al. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology. 2004;209(1):46-9.
Iraji, F., Vali, A., Asilian, A., Shahtalebi, M. A., & Momeni, A. Z. (2004). Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology (Basel, Switzerland), 209(1), 46-9.
Iraji F, et al. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis. Dermatology. 2004;209(1):46-9. PubMed PMID: 15237267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. AU - Iraji,Fariba, AU - Vali,Anahita, AU - Asilian,Ali, AU - Shahtalebi,Mohamad-Ali, AU - Momeni,Ali Z, PY - 2003/02/17/received PY - 2004/02/14/accepted PY - 2004/7/9/pubmed PY - 2004/10/8/medline PY - 2004/7/9/entrez SP - 46 EP - 9 JF - Dermatology (Basel, Switzerland) JO - Dermatology VL - 209 IS - 1 N2 - BACKGROUND: Cutaneous leishmaniasis is an endemic disease in developing countries. The first-line drugs for its treatment are the pentavalent antimony compounds such as meglumine antimoniate (MA). High cost, side effects, multiple injections and incomplete efficacy are limitations of this therapy. Zinc sulfate (ZS) has been reported to be effective in the treatment of cutaneous leishmaniasis. OBJECTIVE: To compare the efficacy of intralesional injections of ZS 2% with those of MA in the treatment of cutaneous leishmaniasis. METHODS: This was a prospective, double-blind, case-control clinical study. 104 patients with typical lesions of acute cutaneous leishmaniasis (ACL) were included. The duration of treatment was 6 weeks. Improvement was evaluated by clinical examination and direct smear. RESULTS: The study was completed in only 66 patients: 35 patients received MA and 31 received ZS. The cure rates were 60% for MA and 83.8% for ZS. After the second and fourth weeks, the efficacy of treatment with ZS was higher than that with MA (p < 0.01), but after 6 weeks no significant differences were observed between the two groups (p > 0.05). CONCLUSION: On the basis of this trial and despite the high number of drop-outs, we consider that the intralesional injection of ZS 2% is an alternative treatment in ACL. SN - 1018-8665 UR - https://www.unboundmedicine.com/medline/citation/15237267/Comparison_of_intralesionally_injected_zinc_sulfate_with_meglumine_antimoniate_in_the_treatment_of_acute_cutaneous_leishmaniasis_ L2 - https://www.karger.com?DOI=10.1159/000078586 DB - PRIME DP - Unbound Medicine ER -